retatrutide benefits clinical trial retatrutide New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide FDA Approval Status 2026:

Unlike traditional diet programs, our treatments address the biological factors influencing weight gain and appetite, making them ideal for long-term results

[PubMed] Thomas MK, Nikooienejad A, Bray R, et al

Enterohormonal changes after digestive adaptation: five-year results of a surgical proposal to treat obesity and associated diseases

I.KoychevI.et al (2025)

CBO estimates that it would cost $1.5 billion to the federal government in the first year alone, rising to $6.1 billion in 2034 (see figure 1)

Balancing Benefits and Risks The decision to use GLP-1 medications involves weighing significant health benefits against potential side effects, including oral health concerns